Atara Biotherapeutics, Inc. (ATRA) — Stock Score Summary

Atara Biotherapeutics, Inc. (ATRA) has a MoatMap StockRank of 16/100 based on Quality (30/100), Value (40/100), and Momentum (30/100) factor scores. The current signal is STRONG SELL. Atara is a highly speculative biotech firm with a weak balance sheet and high cash burn, representing a binary risk profile rather than an asymmetric quality compounder.

Atara Biotherapeutics, Inc. is a pioneer in allogeneic T-cell immunotherapy, developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune conditions. The company competitive moat is established by its proprietary Epstein-Barr virus T-cell platform, which enables the creation of off-the-shelf, targeted immunotherapies like Ebvallo. It operates as a leading clinical-stage biotechnology player at the forefront of cellular medicine.

Key Financial Metrics

Price$9.77
Market Cap$101M
P/E (Forward)6.27
Price/Book-2.34
Return on Invested Capital687.2%
Gross Margin-11.7%
Operating Margin-652.9%
Revenue Growth-99.5%
Free Cash Flow$-6M

Atara Biotherapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Atara Biotherapeutics, Inc.’s (ATRA) StockRank?
MoatMap’s StockRank for Atara Biotherapeutics, Inc. (ATRA) is 16/100, with a Strong Sell signal. It is a composite of Quality (30), Value (40), and Momentum (30) factor ranks across MoatMap’s 19,000+ stock universe.
Does Atara Biotherapeutics, Inc. have an economic moat?
Atara Biotherapeutics, Inc. (ATRA) has a Quality factor score of 30/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Atara Biotherapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Atara Biotherapeutics, Inc. (ATRA) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Atara Biotherapeutics, Inc. in?
Atara Biotherapeutics, Inc. (ATRA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksATRA deep dive reportAI ChampionsHow we score stocksSense-check another stock